Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® ...

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which ...

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust late-stage pipeline that should lead to important approvals.10 stocks we ...

(AXSM) on Monday reported a loss of $48 million in its second quarter. On a per-share basis, the New York-based company said it had a loss ...

Axsome Therapeutics reported record total product revenues of $150 million for the quarter, marking a 72% increase year-over-year and a 24% increase quarter-over-quarter. This impressive growth ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics (AXSM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook ...

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ:AXSM) following the company’s R&D Day. The research firm highlighted ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Discover Axsome Therapeutics' Q2 2025 earnings highlights, including 72% revenue growth, new product launch SYMBRAVO, and promising neuroscience ...